SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Microcap Kitchen Canadian Stocks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ayeyou who wrote (24596)6/2/2014 10:59:09 AM
From: zen_lunatic420  Read Replies (1) of 49402
 
MBX: Microbix is now profitable in their core business of providing infectious disease antigens, most notably for the increasing demand for Dengue Fever test kits, as major pharma companies work towards developing an effective vaccine as well. Also, Microbix pipeline of products is much closer to the market than a drug candidate in preclinical testing. Lumisort won't require a FDA drug approval, Virusmax lawsuit is a year or two away from trial, but an interested licensee could likely begin using the technology with a relatively simple modification to an existing approval, and their Urokinase is already FDA approved, they would just need the FDA to approve the new manufacturing plant, if and/or when they find a partner.

I have no qualm with you discussing TLT here, but think that off-base analogy was perhaps a bit off base itself.

Good luck, I do find it interesting and will put it on my watchlist.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News